Antibody Therapeutics

Explore antibody therapeutics, from monoclonal antibodies to innovative formats like ADCs & bispecifics, revolutionizing treatment for cancer, autoimmune, and infectious diseases.

Explore how fully human antibodies reduce immunogenicity, enhance therapeutic efficacy, and enable personalized treatments, supported by advanced transgenic technologies.

Explore antibody structure, molecular dynamics, and engineering advancements like bispecifics and scFv, driving innovation in therapeutic design and applications.

Explore the evolution, applications, and impact of therapeutic antibodies across disciplines, from cancer and autoimmune diseases to infectious & neurological disorders.

Explore how epitope characterization enhances antibody therapeutics, ensuring specificity, reducing cross-reactivity, and advancing targeted treatment strategies.

Explore antibody therapeutics for infectious diseases, targeting viral & bacterial pathogens. Learn about prophylaxis, treatment, humanized mAbs, & ADCs in fighting infections.

Explore the role of anti-idiotype antibodies & critical reagents in therapeutic antibody development, ensuring specificity, potency & safety in drug testing

Discover how Contract Research Organizations (CROs) streamline therapeutic development through expertise, cost-effectiveness, and scalability, driving innovation in biotech and pharma.

Examine how CHO cell line development and optimized upstream processing drive therapeutic antibody production, ensuring high yields and therapeutic efficacy.

Discover the methods like ELISA, SPR, and AI-driven high-throughput screening used to identify therapeutic antibodies, ensuring specificity, safety, and efficacy.

Learn how scientists identify antigens for therapeutic antibodies using genomics, bioinformatics, and functional studies, ensuring disease relevance and drugability.

Explore the role of monoclonal antibodies in combating COVID-19, including their ability to neutralize SARS-CoV-2. Learn about therapeutic developments like Actemra & challenges posed by emerging variants with Biointron.